tiprankstipranks
Hikma Pharmaceuticals PLC (HKMPY)
OTHER OTC:HKMPY
US Market
Holding HKMPY?
Track your performance easily

Hikma Pharmaceuticals (HKMPY) Income Statement

34 Followers

Hikma Pharmaceuticals Income Statement

Last quarter (Q4 2022), Hikma Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Hikma Pharmaceuticals's net income was $―. See Hikma Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-$ 2.88B$ 2.52B$ 2.55B$ 2.34B$ 2.21B
Cost of Revenue
-$ 1.49B$ 1.28B$ 1.25B$ 1.14B$ 1.12B
Gross Profit
-$ 1.39B$ 1.24B$ 1.30B$ 1.20B$ 1.09B
Operating Expense
-$ 920.00M$ 755.00M$ 704.00M$ 641.00M$ 639.00M
Operating Income
-$ 470.00M$ 483.00M$ 597.00M$ 560.00M$ 449.00M
Net Non Operating Interest Income Expense
-$ -85.00M$ -45.00M$ 39.00M$ 22.00M$ 1.00M
Other Income Expense
-$ 25.00M$ 11.00M---
Pretax Income
-$ 281.00M$ 233.00M$ 544.00M$ 558.00M$ 491.00M
Tax Provision
-$ 89.00M$ 42.00M$ 124.00M$ 128.00M$ 4.00M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-$ 190.00M$ 188.00M$ 421.00M$ 431.00M$ 486.00M
Basic EPS
-$ 0.86$ 0.84$ 1.82$ 1.83$ 2.01
Diluted EPS
-$ 0.85$ 0.84$ 1.81$ 1.81$ 2.00
Basic Average Shares
-$ 220.86M$ 224.00M$ 231.00M$ 236.00M$ 242.00M
Diluted Average Shares
-$ 222.37M$ 225.00M$ 233.00M$ 238.00M$ 243.00M
Dividend Per Share
-$ 0.72$ 0.37$ 0.52$ 0.46$ 0.43
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-$ 2.40B$ 2.03B$ -1.96B$ -1.78B$ -1.76B
Net Income From Continuing And Discontinued Operation
-$ 190.00M$ 188.00M$ 421.00M$ 431.00M$ 486.00M
Normalized Income
-$ 312.75M$ 369.73M$ 419.64M$ 402.98M$ 349.71M
Interest Expense
------
EBIT
-$ 373.00M$ 307.00M$ 600.00M$ 614.00M$ 542.00M
EBITDA
-$ 373.00M$ 307.00M$ 744.00M$ 705.00M$ 542.00M
Currency in USD

Hikma Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis